Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Jun

Today In Oncology

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Related Videos

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

AGA Recommends Colonoscopy Over Alternative Colorectal Cancer Screening Methods

AI-Assisted Tumor Volume Response Criteria Outperform Physician Assessments and RECIST Criteria in Pleural Mesothelioma

Overall Survival With EBRT in Hepatocellular Carcinoma

HCC TACE Plus STRIDE With or Without Lenvatinib

St Jude Redesignation Marks Collaboration With WHO Toward Improved Pediatric Cancer Outcomes Globally